Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
3163572
Reference Type
Journal Article
Title
High-sensitivity cardiac troponin I at presentation in patients with suspected acute coronary syndrome: a cohort study
Author(s)
Shah, AS; Anand, A; Sandoval, Y; Lee, KK; Smith, SW; Adamson, PD; Chapman, AR; Langdon, T; Sandeman, D; Vaswani, A; Strachan, FE; Ferry, A; Stirzaker, AG; Reid, A; Gray, AJ; Collinson, PO; Mcallister, DA; Apple, FS; Newby, DE; Mills, NL; High-STEACS investigators
Year
2015
Is Peer Reviewed?
1
Journal
The Lancet
ISSN:
0140-6736
EISSN:
1474-547X
Volume
386
Issue
10012
Page Numbers
2481-2488
Language
English
PMID
26454362
DOI
10.1016/S0140-6736(15)00391-8
Abstract
BACKGROUND:
Suspected acute coronary syndrome is the commonest reason for emergency admission to hospital and is a large burden on health-care resources. Strategies to identify low-risk patients suitable for immediate discharge would have major benefits.
METHODS:
We did a prospective cohort study of 6304 consecutively enrolled patients with suspected acute coronary syndrome presenting to four secondary and tertiary care hospitals in Scotland. We measured plasma troponin concentrations at presentation using a high-sensitivity cardiac troponin I assay. In derivation and validation cohorts, we evaluated the negative predictive value of a range of troponin concentrations for the primary outcome of index myocardial infarction, or subsequent myocardial infarction or cardiac death at 30 days. This trial is registered with ClinicalTrials.gov (number NCT01852123).
FINDINGS:
782 (16%) of 4870 patients in the derivation cohort had index myocardial infarction, with a further 32 (1%) re-presenting with myocardial infarction and 75 (2%) cardiac deaths at 30 days. In patients without myocardial infarction at presentation, troponin concentrations were less than 5 ng/L in 2311 (61%) of 3799 patients, with a negative predictive value of 99·6% (95% CI 99·3-99·8) for the primary outcome. The negative predictive value was consistent across groups stratified by age, sex, risk factors, and previous cardiovascular disease. In two independent validation cohorts, troponin concentrations were less than 5 ng/L in 594 (56%) of 1061 patients, with an overall negative predictive value of 99·4% (98·8-99·9). At 1 year, these patients had a lower risk of myocardial infarction and cardiac death than did those with a troponin concentration of 5 ng/L or more (0·6% vs 3·3%; adjusted hazard ratio 0·41, 95% CI 0·21-0·80; p<0·0001).
INTERPRETATION:
Low plasma troponin concentrations identify two-thirds of patients at very low risk of cardiac events who could be discharged from hospital. Implementation of this approach could substantially reduce hospital admissions and have major benefits for both patients and health-care providers.
FUNDING:
British Heart Foundation and Chief Scientist Office (Scotland).
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity